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Abstract
Background: Injection drug use is an important public health problem. Epidemiological understanding of this
problem is incomplete as longitudinal studies in the general population are difficult to undertake. In particular little
is known about early life risk factors for later drug injection or about the life course of injection once established
including the influence of medical and social interventions.
Methods: Individuals thought to be drug injectors were identified through a single primary medical care facility in
Edinburgh between 1980 and 2006 and flagged with the General Registry Office. From October 2005 - October
2007, these cases were traced and invited to undergo interview assessment covering early life experience,
substance use, health and social histories. Age and sex matched controls for confirmed cases (alive and dead) were
later recruited through the same health facility. Controls for living cases completed the same structured interview
schedule. Data were also collected on cases and controls through linkage to routine primary care records, death
registrations, hospital contact statistics and police and prison records. All interviews were conducted with the
knowledge and permission of the current GP.
Results: The initial cohort size was 814. At start of follow up 227 had died. Of the remaining 587: 20 had no
contact details and 5 had embarked from the UK; 40 declined participation; 38 did not respond to invitations; 14
were excluded by their GP on health or social grounds and 22 had their contact details withheld by administrative
authorities. 448 were interviewed of whom 16 denied injection and were excluded. Of 191 dead cases with
medical records 4 were excluded as their records contained no evidence of injection. 5 interviewed cases died
before follow up was concluded though these individuals were counted as “live” cases. 1 control per case (dead
and alive) was recruited. Linkage to Scottish Morbidity Records data (available from 1981 onwards) on general
acute inpatient and day cases, mental health inpatient and day cases and cancer was provided by Information
Services, NHS Scotland, for all cases interviewed and all dead cases. The Scottish Prison Service provided records
for 198 (46%) of cases interviewed, 48 cases not interviewed and 34 (18%) of dead cases. For a sub-sample of 100
interviewees a search of the Lothian and Borders police database was made for official criminal records and 94 had
criminal records. Data linkage for controls is ongoing.
Conclusions: Injecting drug users recruited from a community setting can be successfully followed-up through
interviews and record linkage. Information from injecting cases is being analysed in terms of injecting patterns and
possible influences on these. Comparisons between cases and controls will allow identification of possibly
modifiable early life risk factors for drug injection and will also clarify the burden of disease associated with
injection and the influence on this of different health and social interventions.
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Illicit injection drug use, particularly of opiates, emerged
as an important public health problem in the second
half of the 20
th century [1,2]. Injection drug users (IDU)
experience increased risk of morbidity and mortality
mainly related to viral and bacterial infections, acciden-
tal overdose, and injection related arteriovenous occlu-
sions [3,4]. Injection drug use also has social costs,
particularly from associated criminality, for injectors,
their families and the community [5]. There is also evi-
dence that blood borne infections acquired by injectors
may be transmitted to their non-injecting sexual part-
ners [6].
There is limited evidence of effective primary or sec-
ondary prevention of injection drug use [7]. The most
evaluated secondary prevention intervention is the pre-
scribing of non-injected substitute drugs, in particular
oral methadone [8]. There is evidence that this can
reduce injection frequency and illicit drug consumption
and is also associated with reductions in morbidity and
mortality [9-12]. It is uncertain whether and how drug
treatment modifies overall duration of drug dependence
and injecting. Existing evidence is mixed; some longitu-
dinal evidence suggests that methadone treatment is
associated with shorter injecting careers [13] whilst
other evidence suggests no beneficial effect of treatment
on mortality amongst recent onset injectors in the com-
munity [14].
Aside from oral substitution treatment, injectable sub-
stitutes have also been evaluated [15], as have various
approaches to supporting detoxification either as an
inpatient or in the community [16]. Outside the health
sphere the main interventions aimed at injection drug
users are those delivered within the criminal justice sys-
tem in the form of custodial and non-custodial sen-
tences that may include an element of drug treatment
but these have been less rigorously evaluated [17,18].
There is currently limited evidence on the effect of all
these interventions when they are delivered in naturalis-
tic settings outside of study conditions. Similarly the
epidemiological understanding of risk and protective
factors, natural history and outcomes of injecting that
might inform the development of more effective inter-
ventions is also deficient. There are several reasons for
this deficiency. Injection drug use is an illegal, clandes-
tine activity undertaken by individuals that often lead
highly marginalised lives and typically experience a high
degree of socio-environmental disadvantage making the
recruitment of representative samples and follow-up dif-
ficult [19]. Indirect estimates of drug injection preva-
lence in some UK cities suggest it is not uncommon
[20,21], at 1-2% of younger adults in most UK cities.
However, attempts to sample IDU through household
surveys fail because of numerous selection biases
[22,23]. Epidemiological studies of drug injectors have
frequently been based on individuals recruited from spe-
cialist treatment settings [24-27], or through a form of
snowball sampling and community recruitment [28-31].
Such individuals are often re c r u i t e da tar e l a t i v e l yl a t e
point in their injecting career and may be atypical.
Moreover, many studies of injectors are cross-sectional
and therefore limited in their ability to inform causal
hypotheses. Prospective, general population based stu-
dies of injectors are extremely rare since injectors are
less likely to be recruited or retained in such investiga-
tions. Another substantial problem facing observational
s t u d i e so fd r u gi n j e c t o r si st h a to fc o n f o u n d i n g .D i s t i n -
guishing genuine causes and consequences of injection
from factors that are mainly markers of the disadvantage
injection drug use is typically associated with is a con-
siderable challenge.
Nonetheless, Injection drug users often have relatively
high levels of contact with various services and official
bodies who may record and hold data relating to these
contacts. These routine data may be a valuable source
of information relevant to epidemiological studies.
In the UK, most medical treatment for injection drug
users is delivered in primary care. Primary care based
treatment for injectors has a longer history in South
East Scotland than in much of the UK because of local
need to respond to an epidemic of HIV infection
amongst drug injectors in the 1980s [32]. The Edin-
burgh Addiction Cohort (EAC) is a community based,
open cohort of opiate injectors presenting to a single
primary medical care facility in North West Edinburgh
between 1980 and 2006 [33]. Cohort members have
been followed up since recruitment through routine
data sources, including their primary care records and
through personal interview. More recently, a cohort of
age and sex matched non-injecting controls has been
recruited through the same primary medical care facility.
Information on these controls is collected from the
same sources as with cases. Cases and controls will be
used to investigate questions around the aetiology of
injection drug use in terms of risk and protective fac-
tors; disease course and the influence on this of expo-
sure to medical and criminal justice interventions and
other factors; and outcomes. Comparisons with non-
injecting controls from the same population as cases
also allows consideration of the issue of socio-economic
confounding.
Methods
Data collection instruments
Cases and controls completed an interviewer-adminis-
tered structured questionnaire (Additional file 1)
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Chief Scientist Office-funded pilot study (May 2004 -
March 2005). Questionnaire domains included early life
family circumstances, social environment and experience
of various types of adversity, education and employment,
licit and illicit drug use, contact with primary and sec-
ondary medical care services and treatments received,
forensic history, relationships and children, sources of
income, homelessness and housing, physical and mental
health. Participant recall of historical events was facili-
tated using the life-grid approach [34] whereby events
are related to personally significant events that can be
anchored to a historical timescale (for example the
deaths of famous people, particular sporting occasions
etc). Questionnaires also incorporated standard instru-
ments including the Audit Scale for Alcohol Depen-
dence, the Fagerstrom Test for Nicotine Dependency,
the Hospital Anxiety and Depression Scale and the EQ-
5D Health-Related Quality of Life. J McK, an experi-
enced community psychiatric nurse, undertook most of
the interviews; JR, MH and JM carried out a smaller
number.
Estimating duration of injecting career
Amongst drug injectors the total number of years inject-
ing was derived by subtracting the year of injection
initiation from the year of last cessation or year of fol-
low-up if still injecting. In order to allow for periods of
injection cessation in this calculation we asked partici-
pants for each year after they started injecting whether
he/she had injected in a given year (yes/no), and if so,
whether he/she had ceased injecting for three months or
longer in that year (yes/no), and number of periods of
injecting cessation (range 1-3 times). “Inject time” was
calculated based on the number of cessations and the
assumption that any given cessation was of three
months duration. Thus, for any given year the value was
set at 0 for those who did not inject in that year; 0.25 if
an individual had three 3 month cessations; 0.5 if an
individual had 2 cessations,0 . 7 5i fa ni n d i v i d u a lh a d1
cessation and 1 if the individual injected throughout the
year. “Inject time” was then aggregated across years to
calculate the number and duration of episodes of inject-
ing and cessation based on the following rules: (1) all
consecutive whole years of injecting form a single period
of injecting; (2) all part years of injecting when they
either preceded or followed by a full year of injecting
are aggregated; (3) two consecutive years with part of
the year injecting are aggregated and any third year
begins a new episode [27] Clearly, inject time is right
truncated as some of the participants are still injecting,
and some that report not injecting at the time of follow-
up may subsequently relapse. The nature of the data
mean that the appropriate analysis of inject time in
relation to survival and cessation must be based on
methods and statistical models that handle discrete time
periods (i.e. aggregated time periods and the number of
events that occur within them) rather than continuous
time, and that to measure duration of injecting a defini-
tion of “final cessation” is required [35,36].
A template for extracting relevant data from primary
care records (Additional file 2) was also used, which
covered areas such as problems in childhood, illicit drug
use and substitution treatment, physical/mental health
problems and blood borne virus data. This template was
also used for extracting information from the primary
care records of dead cohort members, along with a sup-
plementary data sheet relating to drug and alcohol use
in the year prior to death and scrutiny of death certifi-
cates for relevant information.
External data sources
In addition to interview data and primary care records,
the individuals were linked to other external data
sources.
1. Scottish Morbidity Register (SMR) data - in order
to identify cohort members that since 1981 have
been admitted to general acute hospital as inpatient
or day cases or mental health ward/hospital as inpa-
tient and day cases, or had cancer registration.
2. The Scottish Prison Service (SPS) used SPS Pris-
oner Records System Version 2 to search their data-
base (initially electronic in 1996 and revised in 2004)
for cases’ prison records and provided data on types
of crimes committed and sentences given to our
cohort members.
3. Lothian & Borders Police provided criminal
record systems containing crimes and disposals for a
sample of 100 interviewees and 19 dead cases.
Searches for the full number of cohort members
could not be carried out due to lack of police
resources.
4. General Register Office (GRO) for Scotland pro-
vided the study with tracing data and death
certificates.
In each case the relevant data custodian was provided
with identifier informati o no nc o h o r tm e m b e r s( f o r
SMR data and data from the GRO this was name, sex,
date of birth and National Health Service (NHS) num-
ber; for police and prison data this was name, sex and
date of birth) to allow matching. Only exact matches on
these fields were accepted. For SMR, Prison and Police
data a single matched file of information up to the date
of matching was provided to the study team. For death
certificates information is provided on a rolling basis as
deaths are registered.
Macleod et al. BMC Public Health 2010, 10:101
http://www.biomedcentral.com/1471-2458/10/101
Page 3 of 13Initially, it was also our intention to attempt individual
linkage to files held by the Edinburgh Social Work
Department. This subsequently proved impossible.
Though the Department were prepared to confirm
whether individuals had a Social Work case file, they
would not allow access to information contained in that
file due to concerns around confidential third party
information.
Recruitment of cases
Cases were recruited between 1980 and 2006 when they
presented at Muirhouse Medical Group with a history
of injection drug use. Throughout the recruitment per-
iod a dedicated research project worker undertook regu-
lar note reviews in an attempt to ensure complete
ascertainment of presenting cases. The project worker
entered cases on a clinical database. Cases were
“flagged” with the GRO for Scotland to allow tracing,
the collection of death certificates and possible linkage
to the Scottish Morbidity Register (SMR). The GRO did
not require individual consent for such flagging and all
cases were therefore flagged.
From 2005, when the present study commenced, indi-
vidual consent was sought from all living cohort mem-
bers contacted for follow up for linkage to the medical
and social administrative databases described above at
the time of interview. All individuals interviewed gave
such consent. The follow up study attempted to contact
all surviving cohort members between October 2005
and September 2007. For those no longer practice
patients, tracing was carried out via GRO, Practitioner
Services and Primary Care Trusts in order to establish
details of patients’ current registered General Practi-
tioner (GP). Where possible GPs were approached
directly, given study information and asked to provide
patient contact details. In some cases direct GP contact
was not possible as current GP was not provided by the
relevant Director of Public Health. In other cases some
GPs were not prepared to provide patient contact
details. In both these latter scenarios GPs and Directors
of Public Health were asked to forward a request for
participation in a follow-up interview to cohort mem-
bers. Where contact details were available these requests
were sent directly to cohort members by the study
team. Cases agreeing to be interviewed were invited to
select their preferred venue from their own home, a site
provided by the researcher (generally a local practice) or
an alternative venue such as a café or a friend’sh o m e .3
cases were hospital in-patients at the time of interview.
Recruitment of controls
Controls were recruited from the current Muirhouse
practice list (approximately 11,000). Potential controls of
the same sex as cases and with age +/- two years of the
age of cases but with no history of injection drug use
were identified on the practice list. Controls were
recruited between January 2008 and July 2009. During
this period two of the research team (JRR and JMcK)
noted all potential controls amongst patients attending
the practice to see a GP or other health professional
each day. These patients were then approached (by
JMcK or JRR), informed of the study and invited to par-
ticipate. This process continued until a sex and age (+/-
two years) control was recruited for each case. Those
who agree gave signed consent and were interviewed at
a time and location of their choice. Controls for living
cases were interviewed using the same schedule as
cases, the same data items were extracted from their
patient notes, and (subject to consent) they were flagged
with the General Register Office for Scotland and the
Office of National Statistics and the Scottish and English
prison services. In addition, controls were asked for con-
sent to linkage with police computer and SMR 1 and 4
databases. Controls for dead cases underwent all the
above assessments (with appropriate consent) other than
personal interview. Controls reporting previously unob-
served or unrecorded injecting drug use, were eligible to
be included as a case, with the reasons for their unob-
served status assessed however no controls reported
injection drug use. Non-injection use of illicit drugs
does not effect control eligibility; this possible explana-
tory factor is measured in both cases and controls so
that its influence can be investigated.
Ethical approval
For the cases study, ethical approval was obtained from
the Lothian Research Ethics Committee 04 (LREC/2003/
7/12). and the same Committee granted ethical approval
for the subsequent controls study (LREC/07/S1104/20.
Results
Recruitment of cases and controls
Figure 1 illustrates the geographic distribution of the
cohort at the close of case recruitment in October 2007.
While many cases still resided in the Edinburgh and
Lothians area, a significant number were now located in
different parts of the UK. 814 individuals (555 males)
were originally included in the EAC and flagged with
the GRO. At the start of the follow-up period 227 of
these had been notified as dead. We attempted to trace
and recruit the remaining 587 as described above. 20
were untraceable and 5 had embarked from the UK. Of
the remaining 562, 22 had their contact details with-
held by either their GP or by local NHS administrative
authorities (generally the Director of Public Health) in
most cases the individual making this decision (that was
generally justified on grounds of confidentiality) offered
to pass on study details. These offers were always taken
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actually received forwarded information and no cases
were successfully recruited through this mechanism. 40
individuals responded to study invitations declining to
participate, 38 individuals did not respond to repeated
contact attempts including home visits. Our protocol
allowed GPs to exclude individuals from the study
where they felt that the individual was either too unwell
to participate or where an invitation might cause dis-
tress. 14 individuals were excluded in this way.
448 individuals were interviewed (85% of the 526 with
whom direct contact by the study team was attempted).
The geographic distribution of interviews in the UK is
shown on Figure 2. All those interviewed gave consent
for all record linkage. 42 individuals interviewed denied
ever injecting drugs. In these cases corroborating infor-
mation was sought from other sources. In 26 cases
reports of injection were previously documented in
their primary care records. Following these disclosures
the 191 available notes of dead cases were searched and
in 4 there was no corroborating evidence that the indi-
vidual had ever been an injector. These 4 were also
excluded leaving 432 live and 223 dead cases. 5 cases
died during the follow-up period after having been
interviewed but for control selection purposes these
were still considered “live” cases as interview data were
available.
The characteristics of cases at recruitment are shown
in Table 1. Three-quarters of cohort participants were
born in Edinburgh. Their average age at their first injec-
tion was 19.9 years and at study recruitment was 26.7
years. Half were recruited within five years of injection
onset.
The characteristics of the cohort at follow-up are
shown in Table 2. More than a quarter of cases (29%)
were deceased by the end of follow-up. Mean years of
follow-up (i.e. year of follow-up/death minus year of
recruitment) for cases was 10.2 years (SD 6.7, range < 1-
25). Of those interviewed (54%), almost one third (31%)
reported current injecting at follow-up, more than two
thirds were in opiate substitution treatment (70%), and
less than one in five had ceased injecting and were
opioid-free. Almost all were smokers (93%) and one in
five were also problem drinkers (20%).
The study has recruited one control per case (i.e. 432
“living” controls and 223 “dead” controls). Comparison
between cases and controls in terms of tobacco and
alcohol use, psychological health status and quality of
life are presented in table 2. Controls showed lower pre-
valence of smoking and problem drinking than cases,
and had better psychological health and quality of life.
Detailed comparisons between cases and controls are
not the subject of this paper and will be reported else-
where. 19 potential controls were invited but declined
Rest of Scotland
47
6%
Dead
232
29%
Rest of Edinburgh 
area
234
29%
Practice 
(Muirhouse area, 
Edinburgh)
245
29%
Abroad
5
1%
England and 
Wales
41
5%
No UK location 
trace via GRO
10
1%
Figure 1 Geographic distribution of the EAC cohort including the 20 misclassified cases (n = 814). “pie diagram” showing the distribution
of cohort members at follow up.
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Page 6 of 13to participate in the study and two “living” controls
agreed to be interviewed but declined consent for record
linkage.
Discussion
Response rate
We interviewed 85% of cohort members who had the
opportunity to respond to a study invitation (though
16 of these individuals were subsequently excluded as
cases on the basis of interview information). A very
small proportion of individuals invited to be controls
declined (see above). Despite our relatively high
response rate amongst cases it is possible that there
may be systematic differences between responders,
non-responders and those declining participation.
Non-response may have occurred in the context of
more chaotic lifestyles with frequent address changes
thus our follow-up may have been biased towards less
problematic individuals. Conversely some non-response
and particularly some instances where individuals
actively declined participation may have reflected situa-
tions where the individual had moved on from a drug
injecting lifestyle. In this situation more problematic
individuals may have been overrepresented amongst
interviewed cases. Systematic differences between
traced and non-traced cohort members are also possi-
ble. For example in some cases failure of tracing (as
distinct from non-response or refusal) might also have
reflected a more chaotic lifestyle with failure to register
with a GP. All prospective studies are prone to bias
resulting from non-response and missing information
and the possible influence of such bias will be dis-
cussed in relation to specific analyses when these are
presented. In this regard it is worth noting that our
success in follow-up was higher than that in several
other UK studies with a considerably shorter follow-up
interval [25,31,37].
Issues related to the questionnaire instrument
The questionnaires used in the structured interviews
included standard instruments on tobacco and alcohol
use, psychological health and quality of life as described
above. A previously validated questionnaire covering all
the domains of interest in our study was not available
therefore a study specific questionnaire was developed.
In developing the questionnaire we sought advice from
various experts. Most of these were senior investigators
in the addictions field with a particular interest in the
epidemiology of IDU who provided guidance on ques-
tionnaire content based on experience in their own stu-
dies and the instruments they had developed for these.
We also sought additional expert advice on use of the
“life grid” interview method to measure early life experi-
ence in adults and advice on specific issues related to
the measurement of criminal histories. The question-
naire was tested for comprehensibility and other aspects
of performance during pilot work and refined where
necessary. The expert input we received provided reas-
surance regarding face validity. No further validation of
the instrument was possible prior to the study indeed
further validation would have been difficult due to lack
of a gold standard for comparison. Triangulation of
some questionnaire measures with measures obtained
through linkage allowed some further validation as dis-
cussed below. A copy of the questionnaire is included as
an appendix to allow readers to judge its probable
validity.
Table 1 Cohort characteristics at recruitment
Characteristic N
Male (%) 794 543 (68.4)
Born in Edinburgh (%) 794 530 (66.7)
Mean age (SD, min-max) at first injection 606* 19.9 (5.1, 11-41)
Mean age (SD, min-max) at recruitment 606 26.7 (6.3, 16-52)
Mean years (SD, min-max) first injection
to recruitment
606 6.9 (5.7, 0-28)
Recruited within 5 years of injection
onset (%)
606 306 (50.5)
* Only 606 cohort members had information on age of first injection
Table 2 Follow-up status of cases and comparison of the
current health status of cases and controls
Follow-up status of cases N = 794 (%) % Interviewed
(N = 432)
Deceased 228 (28.7) 0.1
a
Interviewed 432 (54.4) 100
Case notes available 654 (82.2) 100
Lost to follow-up 139 (17.5) -
Mean years follow-up 10.2 (SD 6.8, range < 1-25)
Current injector 135 31.3
Current OST 302 70.0
Opiate free
1 75 17.4
Controls vs. cases health
status
% Controls (n = 432) % Cases (n = 432)
Smoker 255 (59.0) 403 (93.2)*
High risk alcohol use
2 60 (13.9) 87 (20.1)#
Anxious
3 87 (20.1) 209 (48.3)*
Depressed
4 49 (11.3) 114 (26.4)*
Mean subjective QoL (SD)
5 63.8 (22.7) 50.3( 23.6)^
Notes: a: Five interviewees subsequently died before the end of the follow-up
period. 1. Not in OST or injecting illicit opiates 2. Based on AUDIT score of ≥
16 which indicates high risk or harmful drinking in the past year [48] 3. Based
on a HADS anxiety subscale score ≥ 11 indicating caseness [49] 4. Based on a
HADS depression subscale score ≥ 11 indicating caseness [49] 5. Mean EqVAS
score, where a score of 0 is worst imaginable health state and of 100 is best
imaginable health state[50]. Chi square test for difference: # p < 0.01, *p >
0.001, ^ t-test for equality of means: p < 0.001.
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The main general limitations of linkage are that linkage
may fail due to unreliability of linking identifiers; a par-
ticular data item may not be present in the linked data
set (which may or may not reflect issues of data comple-
teness) and that the validity of the measures in the
linked data set may be compromised - basically because
they were not collected with the research purpose for
which they are now being used in mind.
With these caveats in mind the success of linkage in
providing comparison records across different data
sources is summarised in table 3. 222 of 223 dead cases
had death certificate information (one case died abroad
and whilst the death was notified no death certificate
was available) and 182 (82%) had full primary care
records available to the study. All but one set of records
n o ta v a i l a b l eh a db e e nd e s t r o y e d ,i nas i n g l ec a s et h e
participant’s last GP declined to provide a copy.
All 432 interviewed live cases had both primary care
records and were successfully linked to the Scottish
Morbidity Register. We were unable to access primary
care records or SMR records on live cases not inter-
viewed, as we had no opportunity to obtain consent.
The Scottish Prison Service (SPS) did not require indivi-
dual consent for record linkage so linkage was
attempted on the full original cohort of 814; records
were available on 288. 206 of these had been inter-
viewed though 8 of these were individuals who denied
ever injecting and were thus removed from cases, 48
were traced but not interviewed and 34 were dead cases.
Lothian and Borders Police required modification of our
original consent form before undertaking linkage. Link-
age was attempted on the first 100 individuals who con-
sented to this to assess the likely yield. 94 of these
individuals had police records though one denied inject-
ing and was removed from cases.
We are in the process of undertaking detailed compar-
isons of data available on study participants from differ-
ent sources and these will be reported separately. For
most data items the most complete source data are
those from interviews of live cases. Recall and social
desirability bias may influence the validity and reliability
of interview information (see below). To an extent this
influence can be assessed through triangulation with
data on an equivalent measure from other sources
though there are limitations on the scope of this. The
medical records of all individuals interviewed are avail-
able for comparison and corroboration of medical his-
tory. 398 individuals reported ever receipt of a
substitute prescription and for 396 of these this was
recorded in their primary care notes - it is possible that
notes may be incomplete. 324 individuals interviewed
reported referral to specialist drug treatment services
though 387 had evidence of such referral in their notes.
The discrepancy may reflect recall bias or the fact that
some individuals may have never attended a specialist
appointment and/or been aware that a referral had been
made. Levels of apparent agreement between interview
information and primary care records for a selection of
data items are presented in table 4. Detailed comparison
Table 3 Comparison records available across different data sources (NB. lack of comparison record does not
necessarily imply failure of linkage as some individuals will not have experienced record generating events in relation
to all data sources)
Data source Records attempted to link Linkage successful
Scottish Morbidity Register (live confirmed cases) 432 432
Primary care records (live confirmed cases) 432 432
Primary care records (dead confirmed cases) 223 182
General Register Office for Scotland (dead confirmed cases) 223 222
Scottish Prison Service (live confirmed cases) 432 198
Lothian and Borders Police (subset of live confirmed cases) 100 94
Table 4 Comparison of agreement across different data sources of selected data items
Variable Reported at interview
(n = 432)
Noted in primary care records
(n = 432)
Agreement (%)
Ever on OST 398 396 99%
Ever injected* 406 393 97%
Ever referred to specialist drug treatment service 324 387 84%
Ever overdosed and been seen by a doctor 214 152 71%
Ever seen a doctor regarding alcohol problems 72 71 99%
Current smoker 403 281 70%
Currently medically unfit for work 300 324 93%
* See text for discussion
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recorded in the SMR has not yet been undertaken.
321 of the 432 cases interviewed reported a history of
past imprisonment and 195 of these had SPS prison
records. Individuals incarcerated outside of Scotland or
before 1996 would not have an SPS record which may
explain some of the apparent discrepancy. 3 individuals
with SPS records denied ever having being imprisoned
at interview. This could reflect either biased reporting
or mistaken identity in linkage. Cases were asked about
childhood rather than adulthood police contact at
interview though lifetime police records were linked as
these also contain information on imprisonment. 58
individuals reported childhood (i.e. up to age 16) police
contact and in 56 cases their police records corrobo-
rated this. Police contact outside of the Lothian and
Borders region would not necessarily be reliably
recorded in the Lothian and Borders database.
Potential biases
Potential biases in our study and their possible influence
are summarised in table 5. A fundamental bias that it is
Table 5 Potential biases, their influence and how this may be mitigated
Potential source of bias Impact of this bias Possible strategies to minimise this and other
relevant considerations
Selection bias with regard to initial case
ascertainment since cases were all service users
and IDU were not selected at onset of injecting
Causes, consequences, natural history and
duration of IDU amongst injectors who do not
present to services may be different
Impossible to avoid however likely to be less of
an issue than in studies where cases are
recruited from specialist clinics as this involves
additional level of selection. In addition, time
from onset of injecting to recruitment in this
study shorter than in most other cohorts.
Survival bias with regard to case follow-up Patterns of association between the factors
under study may have been different amongst
living compared to dead cohort members
Information on most factors of interest was
available through record linkage on both living
and dead cohort members
Selection bias with regard to case follow-up.
Cases successfully followed up were willing to
be interviewed. Unwillingness to be
interviewed may have reflected either more
chaotic current circumstances or a reluctance
to discuss long resolved drug problems.
Patterns of association between the factors
under study may be different amongst those
lost to follow-up. Outcomes of IDU may have
either been over or underestimated
Impossible to avoid though loss to follow-up
was relatively low and much was due to
structural factors (e.g. GP unwillingness to
recruit) unlikely to be related to participant
characteristics
Selection bias with regard to control
recruitment as controls were all attending a
health facility
If controls were more likely to have health
problems than the general population this may
have diluted associations between some risk
factors and outcomes in case-control
comparisons
The majority of the population use primary care
services relatively regularly often for reasons
unrelated to a significant health problem and
any “unhealthy participant” effect is therefore
likely to be small
Selection bias with regard to control
recruitment as controls may not have been a
representative sample of service users
Potential controls declining recruitment may
have been different from those agreeing with
regard to the factors under study
Consecutive eligible service users were
approached during control recruitment. Only 3%
declined suggesting substantial bias is unlikely
Selection bias with regard to control
recruitment as controls were not recruited at
the same time as cases
To be recruited controls must be alive and
resident in the practice area. Despite age and
sex matching this may have introduced bias.
Impossible to avoid as control selection from
reconstructed historical practice list was
unfeasible (see text). Impact may not have been
substantial since healthier controls would be
both more likely to be living but may also have
been more likely to leave practice area. These
influences would tend to cancel each other out
in terms of resulting bias.
Social desirability bias in relation to interview
measures
Cases may have been more likely to disclose
drug use and other socially sensitive behaviours
and exposures leading to overestimation of the
association between these factors and IDU
Assurances of confidentiality and good
relationship with practice team should have
mitigated this. Where possible objective
corroboration with measures collected through
linkage was sought
Recall bias in relation to interview measures Case recall of some early life exposures may
have been influenced by their own beliefs
around causes of IDU leading to overestimation
of the association between these factors and
IDU. Substance use may also have impaired case
recall of previous exposures leading to
underestimation of the association between
these factors and IDU.
Use of the life-grid approach should have
mitigated this. Where possible objective
corroboration with measures collected through
linkage was sought
Strong association between disadvantage and
IDU may lead to confounding of case-control
comparisons
Some apparent effects of both IDU itself and
possible risk factors may in reality be effects of
other correlates of disadvantage
Recruitment of controls from the same
community as cases should mitigate any bias of
this type and measurement of individual social
position allows further adjustment
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cases were derived from individuals attending a health
facility and disclosing injection drug use. Study mechan-
isms should have ensured that our ascertainment of
these individuals was reasonably complete. It is, how-
ever, possible that some individuals disclosed injection
drug use that was never recorded in their notes and that
these cases were not identified by the study. It is likely
that cases who were identified were an incomplete sam-
ple of drug injectors in the community. Anecdotal evi-
dence suggests that a high proportion of injectors in the
local community sought care in relation to their drug
use at Muirhouse mainly because the practice had a
reputation for a sympathetic attitude towards drug users
and a relative readiness to prescribe substitute drugs.
Because of these factors it is likely that our cohort
represented a high proportion of problem opiate injec-
tors in the community. Occasional injectors and those
able to “control” their use would have had less reason to
identify themselves to the practice as the potential
stigma attached to this may have been perceived to out-
weigh any possible benefit. Such injectors are therefore
likely to have been under-represented in our cohort. 40
out of 472 (8%) eligible living cases declined to partici-
pate in follow up (28 male, 12 female, mean age 40
years). The majority (80%) of these individuals were no
longer patients at Muirhouse and, since they had
declined consent, limited information was available on
which to base a comparison with cases who did partici-
pate. Most individuals declining participation in follow
up gave no reason for this decision. Of the two that did
both stated that injection drug use was a part of their
l i f et h a tt h e yh a d“moved on” from. It is possible that
this reason was more widespread amongst those declin-
ing follow up which may have biased the sample
towards individuals with more enduring drug problems,
however since the proportion declining follow up was
small overall such bias is unlikely to have been a sub-
stantial influence.
There are also potential selection biases between cases
and controls, primarily as the controls are living and
still patients at Muirhouse. We determined through a
pilot study that it was not feasible to reconstruct the
historical practice list back to the time of recruitment of
all the cases, thereby allowing selection of retrospective
controls and avoiding this bias. Further, we felt that the
selection of historical controls no longer in contact with
the practice would introduce practical and ethical pro-
blems of follow-up since unlike cases these individuals
had not consented to tracing. Even if ethical approval
for tracing were granted we felt that response rates
amongst these controls (given our experience of the
administrative hurdles during follow-up of the cases)
would probably be low. Information collected at
interview is subject to the bias normally associated with
self-report in particular social desirability and recall
b i a s e s .I ti sp o s s i b l et h a tt h e s em a yh a v ed i f f e r e d
between cases and controls. For example cases may be
more likely to report (rather than experience) adverse
childhood exposures and may also be less influenced by
social desirability considerations in relation to their
reports of drug use and other socially disapproved beha-
viours. Our use of the life-grid interview method, assur-
ances around confidentiality and the good relationship
between the practice and its patients should mitigate
these considerations to an extent. Broadly, controls are
comparable to the cases i.e. representative of the popu-
lation that generated the cases which is the critical issue
with regard to validity of case control comparisons [38].
19 potential controls (16 male, 3 female, mean age 43,
3% of the total 655 required) declined participation.
Again since these individuals had not consented to
study participation no comparison was possible between
them and those who did consent in terms of the vari-
ables under study. Amongst those who gave a reason for
non-participation, inconvenience was a common expla-
nation cited. Given that the proportion of potential con-
trols declining participation was very small it seems
unlikely that this would have introduced substantial bias.
Natural History
Population surveys and longitudinal studies of IDUs give
two very different pictures of injecting duration, stem-
ming partly from distinct selection biases. Population
surveys under-represent current IDUs; and longitudinal
surveys tend to under-represent non-dependent IDUs
and those with short duration. Thus psychiatric morbid-
ity surveys in UK [39] and US [40] suggest that of peo-
ple who report ever using heroin only 25 to 35% were
dependent and used for sustained periods of time, and
therefore that the average duration across all IDUs and
heroin users estimated from these surveys would be
comparatively short. It is possible to obtain unbiased
estimates of duration of use from biased population sur-
vey data, the ability to do this relies on the availability
of additional information difficult to collect [41,42].
In contrast, many longitudinal studies of IDUs empha-
sise the potentially long duration and high mortality
associated with injecting heroin use. For example, a
recent analysis of heroin trends in Switzerland [43] esti-
mated a mean duration of 25 years. Further, most mod-
els of injecting assume a single cessation episode and a
continuous duration, which we know is not realistic as
injecting drug use typically is a chronic relapsing
condition.
Richer descriptions of injecting duration are becoming
available from a limited number of cohorts. For exam-
ple, analyses of the California Addiction Cohort suggest
Macleod et al. BMC Public Health 2010, 10:101
http://www.biomedcentral.com/1471-2458/10/101
Page 10 of 13that for active participants who had injected within five
years of the previous interview approximately 15% were
abstinent ten years later; whereas of those who had not
i n j e c t e df o rl o n g e rt h a nf i v ey e a r sa p p r o x i m a t e l y7 5 %
remained abstinent 10 years later [44]. Participants from
the Amsterdam Addiction Cohort reported over 2 peri-
ods of injecting per person (range 1 to 8) and over
1100 periods of cessation during an average 9 year fol-
low-up [45]. The mean duration of cessation was 13
months; with approximately half relapsing within the
year and 85% by five years. In addition, an analysis of
the ALIVE cohort from Baltimore reported that
approximately 70% of IDUs ceased drug use after an
average of 4 years, but with 75% relapsing within an
average of one year [46].
Information on cessation also is provided by observa-
tional cohort studies that recruit drug users from specia-
list treatment. For example, the National Treatment
Outcome Research Study (NTORS) reported that five
years after recruitment, 25-33% of the sample were no
longer regular heroin and/or injecting drug users
[25,47]. The Drug Outcome Research Study (DORIS) in
Scotland reported that 8% of subjects were entirely
“drug (i.e. opiate) free” after 33 months follow-up; but if
licit opiate substitution therapy was excluded from the
definition of opiate use then approximately 13% were
“abstinent” at follow-up [26]. Using data from these
cohorts it is not possible to estimate the long term
impact of treatment on injecting duration, partly
because follow-up is too short but also because selection
is conditional on exposure to treatment.
Similarly, long term cohorts such as the ALIVE and
Amsterdam cohorts may suffer from selection biases
since participants were recruited on average later than
10 years after onset of injecting [28,45]. This may have a
strong influence on the estimation of the cessation rates
as considerable amount (40 to 60%) of injecting history
is unobserved and, particularly, those IDUs with short
injecting duration will be considerably under-
represented.
Data from EAC will provide additional insight on
injecting natural history. The EAC cohort has, on aver-
age, less unobserved periods of injecting before recruit-
ment than other current cohorts, although it also has
less frequent follow-up. The challenge of new analyses
of natural history and injecting duration will be to: a)
exploit fully the information from the follow-up data,
which are interval censored data i.e. only the current
status (injecting or not) of each individual is known,
rather than the precise date of ceasing injection and
relapsing; b) address the potential multiple biases affect-
ing the data, including recruitment (or left truncation)
and follow-up biases. Left truncation refers to fact that
subjects were recruited conditionally on being current
injectors and relates to potential selection bias in favour
of IDU with longer periods of injecting. There will also
be right truncation in that some subjects have not yet
ceased injecting.
We believe that the above challenges can be accom-
modated in a modelling framework such as that in
figure 3 Here a multi-state model describes the injecting
history in terms of five states: starting injecting; cessa-
tion of injecting; relapse into injecting; permanent absti-
nence from injecting; and death. The rates between the
stages govern the average time subjects spend in each
stage. Thus, q1 the rate of cessation for IDU that will
relapse, and q9, the rate of cessation for people who
become abstinent, together with q5 determine the
length of time spent in first period of injecting. Analo-
gously, the rates q2 (relapse), q3 (recovery in people
that may later relapse), and q4 (abstinence), together
with the death rates (q6, q7) determine the average time
of injecting and non-injecting between injecting periods.
This modelling approach is flexible and can allow rates
to change with covariates (such as socio-demographic
characteristics, age of onset, and exposure to treatment)
Starting 
injecting  Cessation  Relapse  Abstinence 
Death 
 q1
 q2
 q3
 q4
 q8
 q7  q6
 q5
 q9
Figure 3 Multi-state model of injecting history. graphical depiction of the multi-state model of injecting history used in the analysis
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Page 11 of 13and can accommodate partial observations and problem
of left and right truncation [41,42].
Conclusions
Injecting drug users recruited from a community setting
can be successfully followed-up through interviews and
record linkage. Injecting life course information collected
will provide basis for analyses of injecting duration.
Further comparisons between cases and controls will
allow identification of possibly modifiable early life risk
factors for drug injection and will also clarify the burden
of disease associated with injection and the influence on
this of different health and social interventions.
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